Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taizhou City Invites Japanese Pharmas to Invest
April 19, 2010
- Arixtra Applied for Treatment of Acute DVT, PE: GSK
April 19, 2010
- JPA Supports Court Decision on Online Sale of Drugs: VP Idei
April 19, 2010
- Nippon Shinyaku Licenses Once-Daily Tramadol from Labopharm
April 19, 2010
- Fulvestrant Approved at 500 mg in EU: AZ
April 19, 2010
- RDKK Launches Elecsys Reagent for RA
April 19, 2010
- Zeria Licenses Hemostatic, Wound Dressing Agents from HemCon
April 19, 2010
- Afinitor, Temodal Transiently Excluded from DPC Payment System
April 19, 2010
- Kobayashi Pharm. Spins Off Medical Device Division
April 19, 2010
- Bayer Integrates Intendis
April 19, 2010
- Requirements for Med Institutions Conducting Regenerative Medicine Notified
April 19, 2010
- Medwatcher Japan Presents Petition on Use of Unapproved Medical Devices
April 19, 2010
- CMIC Completes Acquisition of Daiichi Sankyo Propharma's Shizuoka Plant
April 19, 2010
- Q&A on Biosimilars Issued
April 19, 2010
- More than Just the Money
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
April 19, 2010
- Alfresa to Tie Up with 4 Wholesalers
April 19, 2010
- Takeda to Enhance Training of Executives with Global Business Capabilities
April 19, 2010
- JSIM Introduces COI Self-Reporting Requirement from April 12
April 19, 2010
- GSK Becomes JCR's Leading Shareholder
April 12, 2010
- Ciprofloxacin DPI Granted Orphan Drug Status in the US
April 12, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…